COLLEGIUM PHARMACEUTICAL, INC 8-K

What Happened
Collegium Pharmaceutical, Inc. (COLL) filed an 8-K reporting the closing of its acquisition of AZSTARYS on May 12, 2026. The company completed the purchase under an Equity Purchase Agreement entered March 19, 2026, paying approximately $650 million in aggregate cash consideration (subject to customary closing adjustments). The purchase was funded with about $350 million of the company’s cash on hand and $300 million drawn from a delayed-draw term loan in its syndicated credit facility. The company may pay up to an additional $135 million if certain future commercial and manufacturing milestones for AZSTARYS are achieved.

Key Details

• Closing date: May 12, 2026; Purchase Agreement signed March 19, 2026.
• Consideration: ≈$650 million cash at closing (adjustable for working capital, debt, cash, transaction expenses).
• Funding: ~$350M cash on hand + $300M from a delayed-draw term loan (part of the Dec 2025 syndicated credit facility).
• Contingent payments: up to $135M tied to commercial and manufacturing milestones.
• Leadership changes (announced May 11, 2026): Scott Dreyer (EVP & Chief Commercial Officer) will depart effective August 30, 2026; Thomas Smith, M.D. (EVP & Chief Medical Officer) will depart after a transition period. Both departures are treated as terminations without cause under their employment agreements.
• Inducement Plan: Board adopted a 2026 Inducement Plan (May 11, 2026) authorizing awards covering 325,000 common shares for new employees; plan was not submitted for stockholder approval per Nasdaq Rule 5635(c)(4).

Why It Matters
The acquisition adds AZSTARYS, a prescription CNS stimulant for ADHD (ages 6+), to Collegium’s portfolio, which could drive future revenue growth if commercial performance is strong. The deal increases the company’s near-term cash outflow and uses debt ($300M term loan), which may affect leverage and liquidity metrics. Potential milestone payments (up to $135M) represent additional contingent obligations. Executive departures at commercial and medical leadership levels may lead to operational transitions during key integration and commercialization phases. Investors should watch future disclosures for integration progress, AZSTARYS sales performance, and any material effects on Collegium’s financials or guidance.